Advertisement

Annals of Hematology

, Volume 97, Issue 11, pp 2265–2266 | Cite as

Localized pain-causing JAK2-V617F-positive myeloproliferation with normal peripheral blood values

  • Magdalena M. Gerlach
  • Christian Arranto
  • Stefan Dirnhofer
  • Alexandar Tzankov
Letter to the Editor

Dear Editor,

Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized morphologically by panmyelosis with erythroid predominance and elevated red cell parameters in peripheral blood. In approximately 98% of cases, a somatic mutation in the tyrosine kinase JAK2 gene can be found ( JAK2-V617F or JAK2 exon 12). Here, we report on a 47-year-old man who was admitted to our hospital because of isolated bone pain in lumbar vertebra one (L1). FDG-PET revealed increased activity in vertebral body L1 (Fig.  1a). Therefore, a surgical biopsy was taken. Histopathologically, marked hypercellularity with erythroid hyperplasia, increased, partially clustered megakaryopoiesis with nuclear atypia (Fig.  1b) and positivity for phosphorylated STAT5 (pSTAT5) (Fig.  1c) as well as left-shifted myelopoiesis with eosinophilia were observed, all together compatible with MPN. Therefore, a hematologic workup was performed. Peripheral blood values were normal except of a slightly decreased...

Notes

Acknowledgements

We would like to thank Professor Radek Skoda for critically reading the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient.

References

  1. 1.
    Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED (2007) Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol 31(2):233–239.  https://doi.org/10.1097/01.pas.0000213338.25111.d3 CrossRefPubMedGoogle Scholar
  2. 2.
    Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S, Tzankov A (2009) Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 22(3):476–487.  https://doi.org/10.1038/modpathol.2008.207 CrossRefPubMedGoogle Scholar
  3. 3.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. International Agency for Research on Cancer, LyonGoogle Scholar
  4. 4.
    Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111(10):4922–4929.  https://doi.org/10.1182/blood-2007-11-125328 CrossRefPubMedGoogle Scholar
  5. 5.
    Fujimi A, Kanisawa Y, Minami S, Kamihara Y, Iwasaki S (2014) Focal 18F-FDG uptake in bone marrow on PET/CT in a patient with JAK2 mutation without overt myeloproliferative neoplasm. Int J Hematol 99(1):1–3.  https://doi.org/10.1007/s12185-013-1473-y CrossRefPubMedGoogle Scholar
  6. 6.
    Mead AJ, Mullally A (2017) Myeloproliferative neoplasm stem cells. Blood 129(12):1607–1616.  https://doi.org/10.1182/blood-2016-10-696005 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE (2011) The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 96(3):450–453.  https://doi.org/10.3324/haematol.2010.033191 CrossRefPubMedGoogle Scholar
  8. 8.
    Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS (2014) JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica 99(9):1448–1455.  https://doi.org/10.3324/haematol.2014.107631 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Magdalena M. Gerlach
    • 1
  • Christian Arranto
    • 2
  • Stefan Dirnhofer
    • 1
  • Alexandar Tzankov
    • 1
  1. 1.Institute of PathologyUniversity Hospital BaselBaselSwitzerland
  2. 2.Department for HematologyUniversity Hospital BaselBaselSwitzerland

Personalised recommendations